These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
252 related items for PubMed ID: 30500997
1. Expression of programmed cell death ligand 1 in non-small cell lung cancer: Comparison between cytologic smears, core biopsies, and whole sections using the SP263 assay. Munari E, Zamboni G, Sighele G, Marconi M, Sommaggio M, Lunardi G, Rossi G, Cavazza A, Moretta F, Gilioli E, Caliò A, Netto GJ, Hoque MO, Martignoni G, Brunelli M, Vacca P, Moretta L, Bogina G. Cancer Cytopathol; 2019 Feb; 127(1):52-61. PubMed ID: 30500997 [Abstract] [Full Text] [Related]
2. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens. Lozano MD, Abengozar-Muela M, Echeveste JI, Subtil JC, Bertó J, Gúrpide A, Calvo A, de Andrea CE. Cancer Cytopathol; 2019 Jul; 127(7):470-480. PubMed ID: 31245924 [Abstract] [Full Text] [Related]
3. Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer. Capizzi E, Ricci C, Giunchi F, Zagnoni S, Ceccarelli C, Gómez BUÁ, Casolari L, Gelsomino F, Trisolini R, Fiorentino M, Ardizzoni A. Lung Cancer; 2018 Dec; 126():9-14. PubMed ID: 30527198 [Abstract] [Full Text] [Related]
4. Programmed death-ligand 1 immunoexpression in matched biopsy and liquid-based cytology samples of advanced stage non-small cell lung carcinomas. Jain D, Sukumar S, Mohan A, Iyer VK. Cytopathology; 2018 Dec; 29(6):550-557. PubMed ID: 29938855 [Abstract] [Full Text] [Related]
5. Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay. Scorer P, Scott M, Lawson N, Ratcliffe MJ, Barker C, Rebelatto MC, Walker J. Diagn Pathol; 2018 Jul 24; 13(1):47. PubMed ID: 30041679 [Abstract] [Full Text] [Related]
8. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Rebelatto MC, Midha A, Mistry A, Sabalos C, Schechter N, Li X, Jin X, Steele KE, Robbins PB, Blake-Haskins JA, Walker J. Diagn Pathol; 2016 Oct 08; 11(1):95. PubMed ID: 27717372 [Abstract] [Full Text] [Related]
9. Concordance of PD-L1 Expression Between Core Biopsy and Resection Specimens of Non-Small Cell Lung Cancer. Gradecki SE, Grange JS, Stelow EB. Am J Surg Pathol; 2018 Aug 08; 42(8):1090-1094. PubMed ID: 29794870 [Abstract] [Full Text] [Related]
10. Comparative analysis of programmed death ligand 1 expression in paired cytologic and histologic specimens of non-small cell lung cancer. Daverio M, Patrucco F, Gavelli F, Airoldi C, Sciortino G, Chiaramonte C, Rena O, Balbo PE, Boldorini RL. Cancer Cytopathol; 2020 Aug 08; 128(8):580-588. PubMed ID: 32463583 [Abstract] [Full Text] [Related]
14. Optimizing PD-L1 evaluation on cytological samples from advanced non-small-cell lung cancer. Bozzetti C, Squadrilli A, Nizzoli R, Lagrasta C, Gasparro D, Majori M, Filippo M, Becchi G, Azzoni C, Campanini N, Pedrazzi G, Zavani A, Silini EM, Tiseo M, Gnetti L. Immunotherapy; 2020 Feb 08; 12(3):183-193. PubMed ID: 32066299 [Abstract] [Full Text] [Related]
15. Formalin fixation for optimal concordance of programmed death-ligand 1 immunostaining between cytologic and histologic specimens from patients with non-small cell lung cancer. Koomen BM, van der Starre-Gaal J, Vonk JM, von der Thüsen JH, van der Meij JJC, Monkhorst K, Willems SM, Timens W, 't Hart NA. Cancer Cytopathol; 2021 Apr 08; 129(4):304-317. PubMed ID: 33108706 [Abstract] [Full Text] [Related]
16. Performance of Ventana SP263 PD-L1 assay in endobronchial ultrasound guided-fine-needle aspiration derived non-small-cell lung carcinoma samples. Chauhan A, Siegel L, Freese R, Racila E, Stewart J, Amin K. Diagn Cytopathol; 2021 Mar 08; 49(3):355-362. PubMed ID: 33142053 [Abstract] [Full Text] [Related]
17. CT-guided transthoracic needle biopsy for evaluation of PD-L1 expression: Comparison of 22C3 and SP263 assays. Beck KS, Kim SJ, Kang JH, Han DH, Jung JI, Lee KY. Thorac Cancer; 2019 Jul 08; 10(7):1612-1618. PubMed ID: 31237079 [Abstract] [Full Text] [Related]
18. PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study. Savic S, Berezowska S, Eppenberger-Castori S, Cathomas G, Diebold J, Fleischmann A, Jochum W, Komminoth P, McKee T, Letovanec I, Jasarevic Z, Rössle M, Singer G, von Gunten M, Zettl A, Zweifel R, Soltermann A, Bubendorf L. Virchows Arch; 2019 Jul 08; 475(1):67-76. PubMed ID: 31127385 [Abstract] [Full Text] [Related]
19. Programmed Death Ligand 1 Testing of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Samples Acquired For the Diagnosis and Staging of Non-Small Cell Lung Cancer. Smith A, Wang H, Zerbo A, Beaudoin S, Ofiara L, Fiset PO, Benedetti A, Gonzalez AV. J Bronchology Interv Pulmonol; 2020 Jan 08; 27(1):50-57. PubMed ID: 31513030 [Abstract] [Full Text] [Related]
20. Programmed cell death ligand 1 expression in cytologic and surgical non-small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations. Mei P, Shilo K, Wei L, Shen R, Tonkovich D, Li Z. Cancer Cytopathol; 2019 Jul 08; 127(7):447-457. PubMed ID: 31025831 [Abstract] [Full Text] [Related] Page: [Next] [New Search]